Future Research Directions Given the expected increase in the prevalence of double diabetes associated with overweight/obesity [61], the use of the highly effective weight loss medications semaglutide and tirzepatide (second-generation incretin analogs) in patients with T1D and LADA may keep on rising in the near future
Practical safeguards: Typical IRB requirements for tirzepatide studies include clear inclusion/exclusion criteria (e.g., pregnancy, pancreatitis history), interim safety analyses, and provisions for managing hypoglycemia or significant gastrointestinal adverse effects
Similarly, in oncology, zinc-based nanomaterials have been used to induce ER stress and the UPR, culminating in immunogenic cell death and enhancing the efficacy of immune checkpoint blockade therapies 181,182
While some patients choose to stay on Semaglutide long-term, others may be able to maintain their weight loss through lifestyle changes once their goal weight is reached
A class of prescription weight-loss drugs is transforming weight management to the point that manufacturers are struggling to keep up with demand
TRIUMPH-CVOT is the cardiovascular outcomes trial, enrolling approximately 10,000 participants with established cardiovascular disease over a 3-4 year timeline, with MACE as the primary endpoint
